Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 13, 2022 07:00 ET
|
Sol-Gel Technologies Ltd.
FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is patent protected until 2040Partner Galderma to launch two...
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
April 25, 2022 07:00 ET
|
Sol-Gel Technologies Ltd.
EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040 Galderma...
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®
April 14, 2022 08:30 ET
|
Sol-Gel Technologies Ltd.
TWYNEO is the first-ever tretinoin and benzoyl peroxide combination to treat facial acneSol-Gel’s U.S. commercialization partner, Galderma, launched TWYNEO® in the U.S. at the Annual Meeting of the...
Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments
March 30, 2022 07:00 ET
|
Sol-Gel Technologies Ltd.
Galderma launched TWYNEO® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially available in Spring 2022.2021 revenue of $31.3...
Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA
March 25, 2022 11:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, March 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and...
Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference
December 22, 2021 16:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded...
Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®
December 21, 2021 07:00 ET
|
Sol-Gel Technologies Ltd.
FDA informs Sol-Gel that it intends to conduct a pre-approval inspection of the production site for EPSOLAY during the week of February 14th, 2022 NESS ZIONA, Israel, Dec. 21, 2021 (GLOBE...
Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
November 11, 2021 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel attains a profitable quarter, reporting total revenues of $8.8 million, net income of $1.3 million and EPS of $0.06Recently obtained FDA approval of TWYNEO® triggers a $3.5 million milestone...
Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
November 09, 2021 07:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic...
Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million
November 04, 2021 07:30 ET
|
Sol-Gel Technologies Ltd.
- Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs - Sol-Gel to retain two generic...